Neurocrine Biosciences (NBIX) Cash & Equivalents (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Cash & Equivalents for 17 consecutive years, with $332.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents rose 25.91% year-over-year to $332.4 million; the trailing twelve-month figure through Jun 2026 stood at $332.4 million (up 25.91% YoY), and the FY2025 full-year result was $713.0 million, up 206.01% from the prior year.
• Cash & Equivalents rose to $332.4 million in Q2 2026 per NBIX's latest filing, from $266.5 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $713.0 million in Q4 2025 and bottomed at $103.8 million in Q1 2023.
• Historically, Cash & Equivalents has averaged $275.6 million across 5 years, with a median of $265.2 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents sank 61.58% in 2023, then surged 281.79% in 2024.
• Over 5 years, Cash & Equivalents stood at $270.7 million in 2022, then fell by 4.29% to $259.1 million in 2023, then dropped by 10.07% to $233.0 million in 2024, then surged by 206.01% to $713.0 million in 2025, then slumped by 53.38% to $332.4 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $332.4 million, $266.5 million, and $713.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.